ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

ViroPharma Incorporated (Nasdaq: VPHM) today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions®.  The Ryze Above program was created for HAE patients prescribed Cinryze, the first and only drug specifically approved to help prevent swelling and/or painful attacks in teenagers and adults with HAE.  

'Ryze Above' is designed to meet the individual needs of patients with HAE enrolled in the CINRYZESolutions support program and are either receiving Cinryze as prophylaxis against their disease or awaiting initiation of therapy.  The program provides educational information about HAE, patient support services, information about Cinryze and the importance of disease prevention, and information on CINRYZESolutions.  Through 'Ryze Above', important resources, interactive tools, and services are available throughout therapy with Cinryze, and can help patients in managing the challenges of living with HAE.

Patients are automatically enrolled in the 'Ryze Above' patient resources program when they enroll in CINRYZESolutions.  Patients will have access to starter kits, travel kits, exclusive online educational materials, resources, and will receive personalized program communications from their 'Ryze Above' program administrators.

Patients in 'Ryze Above' will receive a starter kit, including:

• Patient brochure for Cinryze
• Brochure for CINRYZESolutions
• HAE disease state brochure
• 'Ryze Above'  Wallet Card

"We recognize that living with hereditary angioedema is challenging, and in many cases can be overwhelming," commented Daniel Soland, ViroPharma's vice president and chief operating officer. "Because HAE is a rare condition, those affected by it can feel alone and isolated.  That's why ViroPharma developed this essential patient program to extend well beyond product access and provide enhanced levels of support and education for these patients."

Added Therese Heimbold, ViroPharma's senior product manager of CINRYZE, "As a new part of our comprehensive patient support program CINRYZESolutions, 'Ryze Above' provides customized resources and education for patients seeking and experiencing prevention of their disease with Cinryze.  Now, as we work with physicians and insurance providers on making prophylaxis with Cinryze available to patients, we can also provide novel tools and new lines of direct and personalized communication to assist those who suffer with HAE."